



# ANUPAM RASAYAN INDIA LTD.

ARILSLDSTX20250523007

Date: May 23, 2025

To, <b>BSE Limited</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001, India <b>SCRIP CODE: 543275</b>	To, <b>National Stock Exchange of India Limited</b> 'Exchange Plaza', C-1, Block-G, Bandra Kurla Complex, Bandra (East), Mumbai-400051, India <b>SYMBOL: ANURAS</b>
---	--

Dear Sir/Madam,

**Subject: Press Release Intimation**

Pursuant to Regulation 30 and other applicable regulations, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed Press Release to be issued by the Company today i.e., Friday, May 23, 2025, regarding the Audited Standalone and Consolidated Financial Results for the quarter and financial year ended March 31, 2025, approved by the Board of Directors of the Company.

This Press Release will also be hosted on the website of the Company at [www.anupamrasayan.com](http://www.anupamrasayan.com).

We request you to kindly take note the same.

Thanking you,

Yours Faithfully,

**For Anupam Rasayan India Limited**

**Anand Desai**  
**Managing Director**  
**DIN: 00038442**

Encl.: As above



**ANUPAM RASAYAN INDIA LTD.**

## **Anupam Rasayan India Limited Reports Q4 & FY25 Results**

**Q4FY25 Total Revenue of ₹5,057 Mn; YOY Growth at 22%**

**FY25 Total Revenue of ₹14,485 Mn; YOY down 4%**

**Surat, May 23, 2025:** Anupam Rasayan India Ltd. (BSE- 543275, NSE- ANURAS, ISIN: INE930P01018), one of India's leading custom synthesis and specialty chemical player, has announced its financial results for the quarter ended March 31, 2025.

### **Consolidated Financial Highlights for year ended March 31, 2025:**

- Total revenue for FY25 was at ₹14,485 million as compared to ₹15,053 million in FY24; down 4% YoY.
- EBITDA (incl. other income) was at ₹4,123 million in FY25 as compared to ₹4,109 million in FY24, this would translate into 28% EBITDA margin in FY25.
- Profit After Tax was at ₹1,600 million in FY25 as compared to ₹1,674 million in FY24.

### **Consolidated Financial Highlights for Quarter ended March 31, 2025:**

- Total revenue for Q4FY25 was at ₹5,057 million as compared to ₹4,130 million in Q4FY24; up 22% YoY.
- EBITDA (incl. other income) was at ₹1,500 million in Q4FY25 as compared to ₹1,047 million in Q4FY24, up 43% and this would translate into 30% EBITDA margin in this quarter.
- Profit After Tax was at ₹629 million in Q4FY25 as compared to ₹405 million in Q4FY24; up 56% YoY.

**Speaking on the performance, Mr Anand Desai, Managing Director, Anupam Rasayan commented,** "Consolidated revenue for the quarter Q4FY25 stood at INR 506 crores registering a growth of 22% YoY and 31% QoQ. Consolidated revenue for the full year FY25 stood at INR 1,448 crores registering a degrowth of 4% YoY. This performance was supported by growth in pharma and polymer coupled with strong performance from Tanfac. Margins have remained consistent this quarter, reflecting our focus on operational efficiency and a favourable product mix.

While H1 FY25 was subdued due to weak macro conditions, I am pleased to share that H2 has shown clear signs of recovery — particularly in Q4 FY25 where we have seen meaningful improvement with sales increasing both year-on-year and sequentially. We remain confident in our ability to return to the historical growth rates achieved prior to the recent slowdown."

### **About Anupam Rasayan India Ltd. (ARIL):**

Anupam Rasayan India Ltd (ARIL) is one of the leading companies engaged in the custom synthesis (CSM) and manufacturing of specialty chemicals in India. Incorporated in 1984, the speciality chemicals major has two verticals: Life science related Specialty Chemicals comprising products related to Agrochemicals, Personal Care and Pharmaceuticals, Other Specialty Chemicals comprising Polymer Additives. The Company caters to a diverse base of Indian and global customers. It is currently manufacturing products for over 75 domestic and international customers, including 31 multinational companies. The Company operates via its six manufacturing facilities in Gujarat, India, with four facilities located at Sachin, Surat and two located at Jhagadia, Bharuch with an aggregate installed capacity of about 30,000 MT, as of March 31, 2025. ARIL offers multistep synthesis and undertakes complex chemical reactions technologies, for a diverse base of Indian and global customers. The Company is focussed on developing in-house innovative processes for manufacturing products requiring complex chemistries and achieving cost optimization.

### **For further details, please get in touch with:**

**IR Contact:**

**Ernst & Young LLP**

Krishna Patel

Email: [krishna.patel2@in.ey.com](mailto:krishna.patel2@in.ey.com)

**PR Contact:**

Sanchi Yadav

Email: [sanchi.yadav@adfactorspr.com](mailto:sanchi.yadav@adfactorspr.com)

Phone: + 91 98336 40764